Imagen de Portada

Letter: Boosting non‐invasive tests—Opportunities and challenges from resmetirom

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Gong Feng, Calvin Q. Pan, Ming‐Hua Zheng
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Letter: Reassessing Tenofovir Alafenamide Use Throughout Pregnancy—A New Horizon in Hepatitis B Therapy. Authors' Reply
por: Xingfei Pan, et al.
Publicado: (2025)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
por: Wenjun Meng, et al.
Publicado: (2024)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
por: Rui Zhang, et al.
Publicado: (2024)

Letter: Resmetirom for treatment of MASH with children and adolescents
por: Yong‐Hai Zhou, et al.
Publicado: (2024)

Letter: Social work and clinical synergy—Optimising health interventions for elderly DGBI populations
por: Rui Zhang, et al.
Publicado: (2024)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
por: Ziheng Calvin Xu, et al.
Publicado: (2025)

Letter: Should ulcerative colitis be monitored more or less invasively?
por: David Laharie
Publicado: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply
por: Matthias Lenfant, et al.
Publicado: (2024)

Letter: Enhancing patient support through social work—Addressing economic challenges and medication non‐adherence in liver disease management
por: Min Wu, et al.
Publicado: (2024)

Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B
por: Xingfei Pan, et al.
Publicado: (2025)

Featured Cover
por: Xingfei Pan, et al.
Publicado: (2025)

Letter: Late Diagnosis of Chronic Hepatitis B—Quantifying the Missed Opportunities and Clinical Consequences
por: Bi‐Yu Gao, et al.
Publicado: (2025)

Letter: Reflections on the role of over‐the‐scope clips in high‐risk upper gastrointestinal bleeding
por: Yajie Wang, et al.
Publicado: (2024)

Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
por: Wah‐Kheong Chan, et al.
Publicado: (2024)

Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention
por: Mo‐Yao Tan, et al.
Publicado: (2024)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
por: Jiamei Wang, et al.
Publicado: (2024)

Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack? Authors' reply
por: Lana Bridi, et al.
Publicado: (2024)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
por: Xiao‐Dong Zhou, et al.
Publicado: (2025)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
por: Leyu Zhou, et al.
Publicado: (2024)

Letter: ‘Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation’
por: You‐Jian Xu, et al.
Publicado: (2024)

Liver function and portal‐systemic shunting quantified by the oral cholate challenge test and risk for large oesophageal varices
por: Tarek Hassanein, et al.
Publicado: (2024)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography
por: Bo Li, et al.
Publicado: (2024)

Letter: Irritable bowel syndrome and antibiotics
por: George F. Longstreth
Publicado: (2024)

Letter: Intestinal Ultrasound‐Prioritising Progress
por: Kacie H. Denton, et al.
Publicado: (2026)

Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis
por: Rutao Lin, et al.
Publicado: (2024)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
por: Jian Wang, et al.
Publicado: (2024)

Letter: Tenofovir Alafenamide—The “Star of Potential” for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials
por: YaoYao Dai, et al.
Publicado: (2025)

Letter: Steroid Tapering—Is Shorter Duration Better?
por: Juntao Lu, et al.
Publicado: (2026)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity?
por: Xiao‐Dong Zhou, et al.
Publicado: (2025)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
por: Kyle Staller, et al.
Publicado: (2024)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy
por: Mustafa Mohamedrashed, et al.
Publicado: (2024)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
por: Tamar Schildkraut, et al.
Publicado: (2024)

Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis
por: Richard Pollok
Publicado: (2025)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition?
por: Fernanda Cristofori, et al.
Publicado: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors?
por: Mathieu Uzzan, et al.
Publicado: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations
por: Christophe Corpechot
Publicado: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
por: Ewan Forrest, et al.
Publicado: (2025)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
por: Hong‐Li Liu, et al.
Publicado: (2026)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
por: Mingsi Zhang, et al.
Publicado: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
por: Yaomin Wang, et al.
Publicado: (2024)